Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Mucinous Adenocarcinoma 1EGFR-Mutated Non-Small-Cell Lung Carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Endometrioid 1Carcinoma in Situ 1Carcinoma 1Breast Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pathologic Complete Response × durvalumab × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡